Medtronic Meets, Core Biz Disappoints - Analyst Blog
February 21 2012 - 7:30AM
Zacks
Medtronic
Inc. (MDT) reported an adjusted EPS of 84 cents
in the third quarter of fiscal 2012, in line with the Zacks
Consensus Estimate, but a couple of cents behind the year-ago
quarter.
Revenues were $4.029 billion in the
quarter, at par with the Zacks Consensus Estimate. However,
after adjusting for revenues from the Physio-Control business,
which is now treated as discontinued operations, revenues came in
at $3.918 billion, up 2% year over year (1% at constant exchange
rates or CER).
Medtronic recorded 45% of its total
sales from the international market during the quarter, which
climbed 7% year over year (6% at CER) to reach $1.773 billion. As a
result of the company’s focus on emerging markets, revenues from
these regions increased 15% (16% at CER) to $395 million.
Segment
Details
Medtronic earns revenues from the
following divisions – Cardiac Rhythm Disease Management (“CRDM”),
Spinal, CardioVascular, Neuromodulation, Diabetes, and Surgical
Technologies. During the quarter, these segments generated
corresponding sales of $1.192 billion (down 2% year over year or
down 3% at CER), $784 million (down 9% or down 10% at CER), $837
million (up 8% reported as well as at CER), $419 million (up 4%
reported as well as at CER), $367 million (up 8% reported as well
as at CER), and $319 million (up 23% or 22% at CER).
Maintaining the lackluster trend
seen in the past few quarters, CRDM continues to disappoint.
Although pacing systems increased 3% at CER to $467 million,
defibrillator sales declined 9% at CER to $674 million. CRDM sales
were affected by declining procedure volume, partially offset by
growth of AF solutions.
While revenues from Core Spinal
dropped 6% at CER to $596 million, Biologics declined 20% at CER to
$188 million. The downside in Biologics was due to continuous
declines in the sales of Infuse (following the publication of
articles in The Spine Journal), partially offset by
revenue growth from Other Biologic products.
Revenue growth in the
CardioVascular segment was driven by robust performance in all
three businesses. Within this segment, revenues from Coronary,
Structural Heart, and Endovascular & Peripheral businesses
increased 3% ($382 million), 10% ($265 million) and 17% ($190
million), respectively.
Endovascular and Peripheral revenue
was driven by successful penetration of the Endurant stent graft
for the treatment of abdominal aortic aneurysms. In Structural
Heart, transcatheter valves continued to show strong growth.
Margins
Gross margin during the reported
quarter increased 45 basis points (bps) to 76.2%. Moreover,
operating margin improved 100 bps year over year to 31.9% with both
selling, general and administrative expenses and research and
development expenses remaining almost unchanged.
Guidance
Medtronic reiterated its revenue
outlook for fiscal 2012. The company, however, tightened its
adjusted EPS guidance to $3.44−$3.47 (previous guidance of
$3.43−$3.50), which considers 4−6 cents of dilution from the Ardian
acquisition. After adjusting for Ardian dilution and 10 cents of
one-time tax benefits received in fiscal 2011, the company expects
to report a 7−8% (6−9%) growth in EPS.
Our Take
We are disappointed with the
company’s performance during the reported quarter on the revenue
front. Having witnessed disappointing performance from the two
biggest segments – CRDM and Spinal – Medtronic is trying every
means to revive growth. This includes penetration of international
markets, portfolio expansion and restructuring initiatives, which
should benefit the company over the long term. Moreover,
acquisitions done over the past few years are contributing to total
revenues, a positive trend that is expected to continue. Meanwhile,
Medtronic has increased its focus on the emerging markets that have
been garnering significant growth.
Despite these measures, economic
uncertainty is impacting procedure volume. Medtronic’s competitors,
Boston Scientific (BSX) and St Jude
Medical (STJ), also face a similar situation. Longer term,
we have a Neutral recommendation on Medtronic.
The stock retains a Zacks #3 Rank
(“Hold”) in the short term.
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From May 2024 to Jun 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2023 to Jun 2024